TransMedics Group WKN: A2PH5P ISIN: US89377M1099 Kürzel: TMDX Forum: Aktien Thema: Hauptdiskussion

TransMedics Group GAAP EPS of -$0.25 beats by $0.15, revenue of $25.7M beats by $6.82M https://seekingalpha.com/news/3901375-transmedics-group-gaap-eps-of-0_25-beats-0_15-revenue-of-25_7m-beats-6_82m • TransMedics Group press release (NASDAQ:TMDX): Q3 GAAP EPS of -$0.25 beats by $0.15. • Revenue of $25.7M (+378.6% Y/Y) beats by $6.82M. • 2022 Financial Outlook: • TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million vs $75.70M consensus, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company's prior year revenue. TransMedics' prior 2022 net revenue guidance was $67 million to $75 million.

TransMedics Reports Third Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-third-quarter-2022-financial-results-301668313.html Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $80 million to $85 million

Irgendwie schon 🙃

Sick!

Deshalb wahrscheinlich auch das: TransMedics Announces Proposed Public Offering of Common Stock https://stockhouse.com/news/press-releases/2022/08/03/transmedics-announces-proposed-public-offering-of-common-stock ...announced today the commencement of a proposed public offering of $100 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the number of shares sold in the offering.   ...

Top aber wann werden die profitabel und sie kämpfen mit Lieferkette Problemen (Fresenius Deutschland, als einziger Lieferant)

TransMedics Reports Second Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2022-financial-results-301597142.html Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ...

TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates https://www.nasdaq.com/articles/transmedics-tmdx-reports-q1-loss-tops-revenue-estimates

https://investors.transmedics.com/news-releases/news-release-details/transmedics-reports-first-quarter-2022-financial-results TransMedics Reports First Quarter 2022 Financial Results

TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication https://www.prnewswire.com/news-releases/transmedics-receives-fda-pma-approval-of-ocs-dcd-heart-indication-301535087.html

https://www.massdevice.com/transmedics-rises-as-revenues-top-wall-street-projections/

TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-fourth-quarter-and-full-year-2021-financial-results-301489026.html

Alle Bio Tech Aktien werden zerstört

TRANSMEDICS POSTS QUARTERLY LOSS PER SHARE OF $0.47 https://www.cmlviz.com/stocks/TMDX/news/b/2021/11/09/transmedics-posts-quarterly-loss-per-share-of-0-47 TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates https://www.nasdaq.com/articles/transmedics-tmdx-reports-q3-loss-lags-revenue-estimates

TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial https://www.prnewswire.com/news-releases/transmedics-announces-positive-top-line-results-from-the-us-randomized-ocs-dcd-heart-trial-301416035.html

TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation https://investors.transmedics.com/news-releases/news-release-details/transmedics-receives-fda-approval-its-ocs-liver-system